Rhythm Pharmaceuticals (NASDAQ: RYTM) is a biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases of obesity. The company generates revenue through product sales of its approved therapies targeting melanocortin-4 receptor pathway disorders. Rhythm is listed on the Nasdaq Global Market and filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, on February 26, 2026. The filing excerpts provided do not contain sufficient detail to characterize segment revenue breakdown, customer concentration, geographic mix, competitive positioning, founding history, or capital structure with the specificity required to report those figures accurately. Based solely on the available filing excerpts, Rhythm operates in the rare disease pharmaceutical space with a focus on genetic obesity conditions.

Revenue model

Product sales of approved pharmaceutical therapies. Specific revenue figures, pricing, or unit economics are not supported by the provided filing excerpts.

Products and services

The filing excerpts reference Rhythm Pharmaceuticals as a pharmaceutical company but do not name specific approved products or pipeline candidates with sufficient detail to list them accurately.

Customers and end markets

Rare genetic disease patients and the healthcare providers who treat them. Specific customer counts or payer mix are not supported by the provided filing excerpts.

Value-chain role

Biopharmaceutical developer and commercial-stage drug manufacturer focused on rare genetic obesity disorders.

Geographic exposure

Listed on the Nasdaq Global Market. Specific geographic revenue breakdown is not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: CHINOOK THERAPEUTICS, INC. Akero Therapeutics, Inc. Avid Bioservices, Inc. Deciphera Pharmaceuticals, Inc. Kyntra Bio Inc Gossamer Bio Inc Kymera Therapeutics Inc SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals Inc